Release Date: July 31, 2025
Expiration Date: July 31, 2026
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in atopic dermatitis (AD). Janus kinase (JAK) inhibitors have emerged as an effective option for patients with moderate to severe AD, particularly those who have not responded adequately to conventional systemic therapies. In this educational program, these experts review the safety data from recent clinical trials of JAK inhibitors in AD management.
This educational activity is an archive of the live symposium held on June 6, 2025.
Target Audience
This educational activity is designed for dermatologists, allergists, immunologists, pediatricians, primary care physicians, nurse practitioners, physician assistants, and other health care professionals involved in diagnosing and treating patients with AD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate emerging safety data and risk profiles of JAK inhibitors, including potential adverse events, long-term safety considerations, and patient-specific risk factors.
- Apply patient-centered strategies to guide the safe initiation and monitoring of JAK inhibitors in AD management.
Andrew Alexis, MD, MPH
Disclosures: Grants (funds to institution): AbbVie, Amgen, Arcutis, Dermavant, Castle, Incyte, Leo; Advisory board/Consulting: AbbVie, Allergan, Almirall, Alphyn, Amgen, Apogee, Arcutis, Bausch Health, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Canfield, Castle, Dermavant, Eli Lilly, Galderma, Genentech, HairDays, Incyte, Johnson & Johnson, L’Oreal, Leo, Novartis, Ortho, Pfizer, Sanofi-Regeneron, Swiss American, Symrise, UCB, VisualDx; Speaker:
Aerolase, Janssen, L’Oreal, Regeneron, Sanofi-Genzyme, Scientis; Royalties:
Elsevier, Springer, Wiley-Blackwell, Wolters Kluwer Health; Equipment:
Aerolase.
Leon Kircik, MD
Disclosures: Grant/Research Support: AbbVie; Ablynx; Acambis; Almirall; Amgen, Inc; Anacor Pharmaceuticals; Anaptys; Arcutis; Arena; Astellas Pharma US, Inc; Asubio; Bausch Health; Berlex Laboratories (Bayer Healthcare Pharmaceuticals); Biolife; BioMimetix; Biopelle; Bristol Myers Squibb; Boehringer Ingelheim; Breckinridge Pharma; Centocor, Inc; Cellceutix; Coherus; Combinatrix; Connetics Corporation; Coria; Dermavant; Dermira; Dow Pharmaceutical Sciences, Inc; Dr Reddy’s Lab; Dusa; Eli Lilly; Exeltis; Ferndale Laboratories, Inc; Foamix; Galderma; Genentech, Inc; GSK; Glenmark Health Point; Idera; Incyte; Intendis; Johnson & Johnson; Leo; L’Oreal; Maruho; Medicis Pharmaceutical Corp; Merck; Nano Bio; Nektar; Nimbus; Novartis AG; Noven Pharmaceuticals; Nucryst Pharmaceuticals Corp; Obagi; Onset; Ortho Neutrogena; Pfizer; Pharmaderm; Promius; QLT; Quinnova; Quatrix; Rapt; Regeneron; Sanofi; SkinMedica, Inc; Stiefel Laboratories; Sun Pharma; Tolerx; UCB; Valeant Pharmaceuticals Intl; Ventyx; Warner-Chilcott; XenoPort; Consultant: AbbVie; Almirall; Amgen, Inc; Anacor Pharmaceuticals; Arcutis; Bristol Myers Squibb; Cassiopea; Cipher; Colbar; Connetics Corporation; Dermavant; Dermira; Dr Reddy’s Lab; Eli Lilly; Exeltis; Ferrer; Galderma; Genentech, Inc; GSK; Intendis; Isdin; Johnson & Johnson; Laboratory Skin Care; Leo; Medical International Technologies; Merck; Merz; Novartis AG; Ortho Neutrogena; Promius; PuraCap; Rapt; Sanofi; SkinMedica, Inc; Stiefel Laboratories, Inc; Sun Pharma; Taro; UCB; Valeant Pharmaceuticals Intl; ZAGE; Speaker’s Bureau: 3M; Abbott Laboratories; Allergan, Inc; Almirall; Amgen, Inc; Assos Pharma; Astellas Pharma US, Inc; Cipher; Connetics Corporation; Dermavant; Dermira; Dermik Laboratories; Embil Pharmaceuticals; Eli Lilly; Exeltis; Ferrer; Galderma; Genentech, Inc; GSK, PLC; Innocutis; Innovail; Johnson & Johnson; Kyowa Kirin; Leo; L’Oreal; Novartis AG; Onset; Ortho Neutrogena; Pediapharma; Pharmaderm; Regeneron; Sanofi; Serono (Merck Serono International SA); SkinMedica, Inc; Stiefel Laboratories, Inc; Sun Pharma; Taro; Triax; UCB; Valeant Pharmaceuticals Intl; Warner-Chilcott; Advisory Board: Aclaris; Almirall; Amgen, Inc; Anacor Pharmaceuticals; Arcutis; Arena; Biogen-Idec; Bristol Myers Squibb; Cassiopea; Cipher; Colbar; Connetics Corporation; Dermavant; Dermira; Dr Reddy’s Lab; Eli Lilly; EOS; Exeltis; Ferndale Laboratories, Inc; Foamix; Galderma; Genentech, Inc; GSK; Glenmark; Incyte; Intendis; Innocutis; Isdin; Johnson & Johnson; Nano Bio; Novartis AG; Ortho Neutrogena; Promius; Quinnova; Sanofi; SkinMedica, Inc; Stiefel Laboratories; Sun Pharma; UCB; Valeant Pharmaceuticals Intl; Warner-Chilcott.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here